Миелодиспластический синдром и хелаторная терапия


Грицаев С.В., Зотова И.И., Кострома И.И., Карпова Н.С., Абдулкадыров К.М.

ФГУ “Российский научно-исследовательский институт гематологии и трансфузиологии” Федерального медико-биологического агентства, Санкт-Петербург
Рассматривается клиническая картина миелодиспластического синдрома (МДС), вариабельность которого находится в диапазоне от многолетнего стабильного течения до случаев трансформации в острый миелоидный лейкоз в течение нескольких месяцев. Анемия – наиболее частый вид цитопении среди больных МДС. Для большинства пациентов единственным методом ее коррекции остается трансфузионная терапия, которая, однако, может становится причиной повреждения миокарда. Для коррекции осложнений, вызванных избытком посттрансфузионного железа, для больных МДС применяется хелаторная терапия. Рассматриваются общие принципы хелаторной терапии, препараты, используемые при ее проведении (в первую очередь деферазирокс). Представлено клиническое наблюдение больной МЛС, получавшей деферазирокс (Эксиджад) по поводу осложнений трансфузионной терапии.

Литература


1. Абдулкадыров К.М. Гематология. Новейший справочник по гематологии. М., 2005. C. 928.


2. Garcia-Manero G. Myelodysplastic syndromes: 2011 update on diagnosis, risk stratification, and management. Am J Hematol 2011;86:491–99.


3. Greenberg PL. Current therapeutic approaches for patients with myelodysplastic syndromes. Br J Haematol 2010;150:131–43.


4. Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs. Blood 2008;112:45–52.


5. Sekeres MA. The epidemiology of myelodysplastic syndromes. Hematol Oncol Clin N Am 2010;24:287–94.


6. Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes. Incidence and survival in the United States. Cancer 2007;109:1536–42.


7. Oliva EN, Dimitrov BD, Benedetto F, et al. Hemoglobin level threshold for cardiac remodeling and quality of life in myelodysplastic syndrome. Leuk Res 2005;29:1217–19.


8. Goldberg SL. Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes. Leuk Res 2007; 31(3):16–22.


9. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005;352:549–57.


10. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006;355:1456–65.


11. Hellstrom-Lindberg E, Willman C, Barrett AJ, et al. Achievements in understanding and treatment of myelodysplastic syndromes. Hematology (Am Soc Hematol Educ Program) 2000:110–32.


12. Lee NR, Park JH, Rhee KS. Acquired long QT syndrome and sudden cardiac death due to secondary hemochromatosis with multitransfusions for severe aplastic anemia. Ann Hematol 2008;87:933–35


13. Porter JB. Concepts and goals in the management of transfusional iron overload. Am J Hematol 2007;82(1):1136–39.


14. Gattermann N, Rachmilewitz EA. Iron overload in MDS – pathophysiology, diagnosis, and complications. Ann Hematol 2011;90:1–10.


15. Messa E, Cilloni D, Saglio G. Iron chelation therapy in myelodysplastic syndromes. Adv Hematol 2010;2010:756289.


16. Knovitch MA, Storey JA, Coffman LG, et al. Ferritin for the clinician. Blood Rev 2009; 23:95–104.


17. Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005;23:7594–603.


18. Tucci A, Matta G, Deplane S, et al. Myocardial iron overload assessment by T2 magnetic resonance imaging in adult transfusion dependent patients with acquired anemias. Haematologica 2008;93:1385–88.


19. Konen E, Ghoti H, Goitein O, et al. No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2 technique. Am J Hematol 2007;82:1013–16.


20. Chacko J, Pennell DJ, Tanner MA, et al. Myocardial iron loading by magnetic resonance imaging T2 in good prognostic myelodysplastic syndrome patients on long-term blood transfusions. Br J Haematol 2007;138:587–93.


21. Wood JC, Tyszka JM, Carson S, et al. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood 2004;103:1934–36


22. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079–88.


23. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007;25:3503–10.


24. Garcia-Manero G, Shan J, Faderl S, et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 2008; 22:538–43.


25. Абдулкадыров К.М., Грицаев С.В., Бессмельцев С.С. и др. Антицитокиновая терапия больных миелодиспластическим синдромом // Вопросы онкологии 2003. № 4. С. 464–66.


26. Park S, Sapena R, Vassilieff D, et al. Correlation between serum ferritin level at diagnosis and survival in lower risk, non-transfusion dependent, MDS patients. A report by the Groupe Francophone Des Myelodysplasies. Blood 2010;116:2916.


27. Rose C, Brechignac S, Vassilief D, et al. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM. Leuk Res 2010;34:864–70.


28. List AF, Baer MR, Steensma D, et al. Iron chelation with deferasirox (Exjade) improves iron burden in patients with myelodysplastic syndromes. Blood 2008;112:аbstr. 634.


29. Greenberg PL, Koller CA, Cabantchik ZI, et al. Prospective assessment of effects on ironoverload parameters of deferasirox therapy in patients with myelodysplastic syndromes. Leuk Res 2010;34:1560–66.


30. Gattermann N, Finelli C, Porta MD, et al. Deferasirox in iron-overloaded patients with transfusion–dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. Leuk Res 2010;34:1143–50.


31. Ghoti H, Fibach E, Merkel D, et al. Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes. Haematologica 2010;95:1433–35.


32. Wood JC, Kang BP, Thompson A, et al. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood 2010;116:537–43.


33. Pennell DJ, Porter JB, Cappellini MD, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood 2010;115:2364–71.


34. Cohen AR, Glimm E, Porter JB. Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major. Blood 2008;111:583–87.


35. Breccia M, Loglisci G, Salaroli A, et al. Deferasirox treatment interruption in a transfusion-requiring myelodysplastic patient led to loss of erythroid response. Acta Haematol 2010;124:46–8.


36. Messa E, Carturan S, Maffe C, et al. Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. Haematologica 2010;95:1308–16.


37. Sanz G, Nomdedeu B, Such E, et al. Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome. Blood 2008;112:аbstr. 640.


38. Leitch HA. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy. Leuk Res 2007;31(3):7–9


Похожие статьи


Бионика Медиа